Skip to main content
. 2022 Sep 29;11(19):e026581. doi: 10.1161/JAHA.122.026581

Figure 3. Eliminating EP4R from kidney tubular epithelial cells leads to exaggerated BP response to Ang II.

Figure 3

(A) KEKO mice have significantly higher MAP after day 14 of Ang II infusion than Controls. (B) The averaged MAP of week 3 to 4 of Ang II infusion was significantly higher in KEKO mice than Controls. (C) The Ang II‐induced MAP increase was exacerbated significantly in KEKO mice. (D) The heart weight/body weight ratio was significantly higher in KEKO mice than Controls following Ang II infusion. Data in (A and B) are expressed as mean±SEM and analyzed by 2‐way ANOVA (factors: genotype and days for A; genotype and treatment for B) with Sidak multiple comparisons tests; data in (C and D) are expressed as median and interquartile range and analyzed by Mann–Whitney test; *P<0.05, **P<0.01, ***P<0.001 vs Control at the same time point or the same treatment (effect size: medium—large for (A), large for (Bfollowing Ang II infusion through D); ### P<0.001 vs Control baseline (effect size: large); &&& P<0.001 vs KEKO baseline (effect size: large); n=9 to 12/group in (A and B); n=8 to 10/group in (C and D); Ang II indicates angiotensin II; BP, blood pressure; EP4R, E‐prostanoid receptor 4; HW/BW, heart weight/body weight ratio; KEKO, kidney epithelial cell‐specific EP4 receptor knockout; and MAP, mean arterial pressure.